Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Zai Lab Limited (NASDAQ:ZLAB) has received an average rating of "Moderate Buy" from analysts, with one hold and six buy recommendations.
• The average price target for Zai Lab shares among analysts is $56.35, with notable ratings from firms like Leerink Partners and Citigroup.
• Insider trading activity includes CEO Ying Du selling 50,000 shares for approximately $1.74 million, indicating a decrease in insider ownership by 8.52%.

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $56.35.

A number of research analysts recently weighed in on ZLAB shares. Wall Street Zen downgraded shares of Zai Lab from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Leerink Partners set a $75.00 price objective on shares of Zai Lab and gave the company an "outperform" rating in a research report on Monday, June 30th. Jefferies Financial Group assumed coverage on shares of Zai Lab in a research report on Monday, August 25th. They issued a "buy" rating and a $52.00 price target on the stock. Finally, Citigroup reiterated a "buy" rating and issued a $69.00 price target (up from $66.00) on shares of Zai Lab in a research report on Monday, August 11th.

Zai Lab Stock Up 1.0%

Shares of Zai Lab stock opened at $32.80 on Friday. The company has a market cap of $3.67 billion, a price-to-earnings ratio of -16.08 and a beta of 1.04. The company's 50 day moving average is $34.78 and its 200 day moving average is $34.01. Zai Lab has a twelve month low of $20.17 and a twelve month high of $44.34.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.37). The company had revenue of $109.98 million for the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. Sell-side analysts expect that Zai Lab will post -2.58 EPS for the current fiscal year.

Insider Buying and Selling at Zai Lab

In other Zai Lab news, CEO Ying Du sold 50,000 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $34.74, for a total value of $1,737,000.00. Following the transaction, the chief executive officer directly owned 536,962 shares in the company, valued at approximately $18,654,059.88. This trade represents a 8.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William Lis sold 13,814 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $35.67, for a total transaction of $492,745.38. Following the completion of the transaction, the director owned 35,106 shares in the company, valued at $1,252,231.02. The trade was a 28.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 215,710 shares of company stock valued at $7,589,684 over the last three months. Insiders own 4.96% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZLAB. Oppenheimer Asset Management Inc. purchased a new stake in shares of Zai Lab in the first quarter worth $603,000. BNP Paribas Financial Markets increased its stake in shares of Zai Lab by 1,439.8% in the fourth quarter. BNP Paribas Financial Markets now owns 19,755 shares of the company's stock worth $517,000 after purchasing an additional 18,472 shares in the last quarter. Raymond James Financial Inc. increased its stake in shares of Zai Lab by 219.6% in the first quarter. Raymond James Financial Inc. now owns 125,967 shares of the company's stock worth $4,552,000 after purchasing an additional 86,547 shares in the last quarter. Northern Trust Corp increased its stake in shares of Zai Lab by 117.8% in the fourth quarter. Northern Trust Corp now owns 49,365 shares of the company's stock worth $1,293,000 after purchasing an additional 26,700 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of Zai Lab in the first quarter worth $420,000. 41.65% of the stock is currently owned by institutional investors.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.